FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, A Athanasiadis, S Kakolyris, S Tsousis, Ch Kouroussis, L Vamvakas, A Kalykaki, G Samonis, D Mavroudis, V Georgoulias, J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, A Athanasiadis, S Kakolyris, S Tsousis, Ch Kouroussis, L Vamvakas, A Kalykaki, G Samonis, D Mavroudis, V Georgoulias

Abstract

To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC). A total of 283 chemotherapy-naïve patients with MCC were enrolled (FOLFIRI arm: n=146; FOLFOXIRI arm: n=137). In the FOLFOXIRI arm, CPT-11 (150 mg m(-2)) was given on d1, L-OHP (65 mg m(-2)) on d2, LV (200 mg m(-2)) on days 2 and 3 and 5-FU (400 mg m(-2) as i.v. bolus and 600 mg m(-2) as 22 h i.v. continuous infusion) on days 2 and 3. In the FOLFIRI arm, CPT-11 (180 mg m(-2)) was given on d1 whereas LV and 5-FU were administered in the same way as in the FOLFOXIRI regimen. Both regimens were administered every 2 weeks. There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and FOLFOXIRI, respectively; P=0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P=0.17), response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P=0.168). Patients treated with FOLFOXIRI had a significantly higher incidence of alopecia (P=0.0001), diarrhoea (P=0.0001) and neurosensory toxicity (P=0.001) compared with patients treated with FOLFIRI. The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature.

Figures

Figure 1
Figure 1
Chemotherapy regimens (A) FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) and (B) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan).
Figure 2
Figure 2
Trial profile.
Figure 3
Figure 3
Kaplan–Meier overall survival of patients treated with FOLFIRI and FOLFOXIRI.
Figure 4
Figure 4
Kaplan–Meier time to tumour progression (TTP) of patients treated with FOLFIRI and FOLFOXIRI.

References

    1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2005. . Assessed March 8, 2005
    1. Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4): 1–3
    1. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046–1050
    1. Cox DR (1972) Regression models and life-tables. J R Stat Soc 34B: 187–220
    1. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leukovorin and fluorouracil bolus with bimonthly high dose leukovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 14: 808–815
    1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
    1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041–1047
    1. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20: 4006–4014
    1. Ferlay J, Bray F, Sankila R (1999) Cancer Incidence, Mortality and Prevalence in the European Union. IARC Press: Lyon
    1. Fischel JL, Rostagno P, Etienne MC (1999) Optimal combination between irinotecan (CPT-11), oxaliplatin (L-OHP) and fluorouracil-folinic acid (FUFOL): experimental data on human colorectal cell lines. Proc Am Assoc Cancer Res 40: 589 (abstract 3882)
    1. Freedman LS (1982) Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1: 121–129
    1. Goldberg R, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30
    1. Grothey AA, Sargent D, Goldberg R, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214
    1. Hsiang YH, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA clevable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082
    1. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
    1. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann of Oncol 13: 308–317
    1. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ (1998) Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as a weekly 24-h infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncl 16: 418–426
    1. National Cancer Institute (1999) Common Toxicity Criteria, version 2.0
    1. O’Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35: 549–556
    1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108
    1. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31: 103–115
    1. Poon MA, O’Connel MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418
    1. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053–1071
    1. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855–1865
    1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. N Engl J Med 343: 905–914
    1. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Diaz-Rubio E (2005) Irinotecan in combination with fluorouracil in a 48-h continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the treatment of digestive tumors study. J Clin Oncol 23: 3545–3551
    1. Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V (2002) A triplet combination with irinotecan (cpt-11) plus oxaliplatin (l-ohp) plus continuous infusion 5-fluorouracil (5-fu) and leucovorin (lv) as first line treatment in metastatic colorectal cancer (MCC): a multicenter phase II trial. J Clin Oncol 20: 2661–2667
    1. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis CH, Agelaki S, Xenidis N, Milaki G, Georgoulias V (2005) Combination of irinotecan (CPT-11) plus bolus followed by continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI) as first line treatment for elderly patients with metastatic colorectal cancer (MCC): A phase II trial. Oncology 69: 384–390
    1. Tanizawa A, Fujimori A, Fujimori Y, Pmmier Y (1994) Comparision of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothesin derivates presently in clinical trials. J Natl Cancer Inst 86: 836–842
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
    1. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22: 229–237
    1. Wadler S, Benson III AB, Engelkinget C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16: 3169–3178

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться